Conclusions: Analysis of the complete mtDNA genome and X-linkage of this five-generation Chinese family revealed that the 1555A > G mutation may lead to deafness.
Objectives: Mutations in mitochondrial DNA (mtDNA) have been found to be associated with sensorineural hearing loss. However, the variable clinical phenotype and incomplete penetrance of mtDNA 1555A > G-induced hearing loss complicate our understanding of this mutation. We aimed to identify whether nuclear genes, mitochondrial haplotypes/variants, and a possible threshold effect are involved in its manifestation in the pedigree.
Methods: We performed clinical, genetic, and X-linkage analysis of a five-generation Chinese family in which all the affected individuals were male.
Results: Clinical evaluation revealed that affected individuals with or without aminoglycoside exposure developed hearing loss extending gradually from 8000 Hz to 4000 Hz and then to 1000 Hz. Using X-linkage analysis and sequencing, we detected an identical homoplasmic 1555A > G mutation in nine individuals, and a previously unreported variant 14163C > T in mtDNA. The new variant 14163C > T coexisted with the 1555A > G mutation in six affected subjects of our pedigree. The previously unreported variant 14163C > T and aminoglycoside exposure may synergize the development of this deafness.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3109/00016489.2011.575794 | DOI Listing |
Otol Neurotol
February 2025
Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Background Introduction: Vestibular schwannoma (VS) tumors typically present with sensorineural hearing loss (SNHL). Losartan has recently demonstrated prevention of tumor-associated SNHL in a mouse model of VS through suppression of inflammatory and pro-fibrotic factors, and the current study investigates this association in humans.
Methods: This is a retrospective study of patients with unilateral VS and hypertension followed with sequential audiometry at a tertiary referral hospital from January 1994 to June 2023.
Otol Neurotol
February 2025
Department of Otolaryngology-Head and Neck Surgery.
Objective: To compare fall risk scores of hearing aids embedded with inertial measurement units (IMU-HAs) and powered by artificial intelligence (AI) algorithms with scores by trained observers.
Study Design: Prospective, double-blinded, observational study of fall risk scores between trained observers and those of IMU-HAs.
Setting: Tertiary referral center.
PLoS One
January 2025
Dept. of Medical Physics and Acoustics, Carl von Ossietzky University of Oldenburg, Oldenburg, Germany.
Music pre-processing methods are currently becoming a recognized area of research with the goal of making music more accessible to listeners with a hearing impairment. Our previous study showed that hearing-impaired listeners preferred spectrally manipulated multi-track mixes. Nevertheless, the acoustical basis of mixing for hearing-impaired listeners remains poorly understood.
View Article and Find Full Text PDFMedicine (Baltimore)
January 2025
Department of Otolaryngology-Head and Neck Surgery, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan.
Cochlear migraine (CM) and cochleovestibular migraine were first reported in 2018. However, the diagnostic criteria and types of CM were still undefined. We proposed a hypothetical criteria for CM as below: A.
View Article and Find Full Text PDFMedicine (Baltimore)
January 2025
Centro de Investigaciones en Anomalías Congénitas y Enfermedades Raras (CIACER), Universidad Iccesi, Cali, Colombia.
Background: Hearing impairment is a prevalent clinical feature in Morquio syndrome (mucopolysaccharidosis IVA or MPS IVA) patients, often presenting in diverse forms: conductive, sensorineural, or a combination known as mixed hearing loss. The mixed form entails a blend of both conductive and sensorineural elements, typically exhibiting a progressive trajectory. This scoping review aimed to comprehensively analyze available evidence pertaining to the pathophysiology, classification, epidemiology, and clinical management of hearing loss in individuals with MPS IVA.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!